New blood test provides fast, accurate diagnosis of tuberculosis in children

NewsGuard 100/100 Score

A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children. The test features excellent specificity, a similar sensitivity as culture tests in combination with speed of a blood test. The promising findings are a major advance for the diagnosis of tuberculosis in children, particularly in tuberculosis-endemic regions.

The study has been published on Sept 1st, 2014 in Lancet Infectious Diseases.

Tuberculosis (TB) in children is a serious public health problem especially in low-resource countries. About one million children per year develop tuberculosis worldwide. Unfortunately, the diagnosis of paediatric TB poses a major challenge. TB symptoms in children are often non-specific and similar to those of common paediatric illnesses, including pneumonia and malnutrition. Further, obtaining adequate respiratory specimens for direct mycobacterial confirmation is problematic. Consequently, there is an urgent need for a more precise, rapid and affordable diagnostic test for childhood tuberculosis.

The new so-called TAM-TB assay is a sputum-independent blood test. It makes use of an immunological phenomenon during tuberculosis disease: During an active infection, the expression of CD27 - a surface marker expressed on mycobacteria specific CD4+ T cells - is lost. Using standard intracellular cytokine staining procedures and polychromatic flow cytometry, the test result is available within 24 hours after blood sampling.

New blood test assessed in tuberculosis endemic regions in Tanzania

The new test was assessed in tuberculosis endemic regions in Tanzania at the Ifakara Health Institute and the NIMR Mbeya Medical Research Center. Sputum and blood samples were obtained from children with tuberculosis symptoms to compare the performance of the new assay with culture tests. For the assessment of the diagnostic performance of the new test, the children were assigned to standardized clinical case classifications based on microbiological and clinical findings. The test proved to have a good sensitivity and excellent specificity.

"This rapid and reliable test has the great potential to significantly improve the diagnosis of active tuberculosis in children " says TB CHILD Program Manager Klaus Reither from the Swiss Tropical and Public Health Institute (Swiss TPH), who coordinated the study.

In a collaborative effort between Swiss TPH and Ludwigs-Maximilians-Universit-t M-nchen (LMU Munich), the test will now be further refined to optimise performance, particularly in HIV-infected children, and to reduce costs. The goal is to finally validate and implement a rapid, robust and accurate diagnostic test for active paediatric tuberculosis that can be used on the district level in resource-poor, tuberculosis-endemic countries.

The diagnostic assay was tested at the Ifakara Health Institute and the NIMR-Mbeya Medical Research Center in Tanzania coordinated by Klaus Reither from the Swiss Tropical and Public Health Institute (Swiss TPH) in collaboration with the clinical immunologists Claudia Daubenberger and Damien Portevin (both Swiss TPH), and Christof Geldmacher (LMU Munich).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer